Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)

Abstract

The kinase inhibitor Ponatinib inhibits an ABL1-JUN signalling axis and alters telomere homeostasis, reduces telomere synthesis, and provokes telomere dysfunction in cancer cells which employ the alternative lengthening of telomeres mechanisms.